BRIEF published on 03/26/2026 at 22:24, 7 months 1 day ago DBV Technologies publishes its financial reports for 2025 AMF Financial Report DBV Technologies DRY VIASKIN®
BRIEF published on 03/26/2026 at 22:24, 7 months 1 day ago DBV Technologies Files 2025 Annual Report and Registration Document Financial Filing Annual Report Universal Registration Document Form 10-K DBV Technologies
PRESS RELEASE published on 03/26/2026 at 22:19, 7 months 1 day ago DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies files 2025 Annual Report on Form 10-K and Universal Registration Document with SEC and AMF. Company developing treatments for food allergies Annual Report Immunotherapy Form 10-K DBV Technologies Food Allergies
BRIEF published on 03/24/2026 at 21:35, 7 months 3 days ago DBV Technologies joins the CAC Mid 60 and SBF 120 indices Euronext Paris SBF 120 DBV Technologies CAC Mid 60 Inclusion Indices
BRIEF published on 03/24/2026 at 21:35, 7 months 3 days ago DBV Technologies Joins CAC Mid 60 and SBF 120 Indices Biopharmaceutical SBF 120 DBV Technologies CAC Mid 60 VIASKIN®
PRESS RELEASE published on 03/24/2026 at 21:30, 7 months 4 days ago DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review DBV Technologies joins CAC Mid 60 and SBF 120 indices on Euronext Paris, increasing visibility among investors. Company focuses on food allergy treatments using VIASKIN patch technology Euronext Paris SBF 120 DBV Technologies Food Allergies CAC Mid 60
BRIEF published on 03/04/2026 at 22:35, 7 months 23 days ago DBV Technologies will participate in investor conferences in March Investor Conferences Biopharmaceutical DBV Technologies March 2026 Citizens Life Sciences
BRIEF published on 03/04/2026 at 22:35, 7 months 23 days ago DBV Technologies Announces Participation in March Investor Conferences Investor Conferences Biopharmaceutical DBV Technologies Food Allergies VIASKIN Patch
PRESS RELEASE published on 03/04/2026 at 22:30, 7 months 23 days ago DBV Technologies to Participate in Upcoming March Investor Conferences DBV Technologies to participate in upcoming investor conferences to present its late-stage biopharmaceutical developments for food allergies. Company uses proprietary VIASKIN patch technology for treatment Investor Conferences Biopharmaceutical DBV Technologies Food Allergies VIASKIN Patch
BRIEF published on 03/03/2026 at 22:35, 7 months 24 days ago DBV Technologies: Update on voting rights and shares Euronext Paris Share Capital Voting Rights Financial Regulations DBV Technologies
Published on 10/28/2026 at 12:30, 9 hours ago Digi Power X to Announce 2026 Q3 Financial Results and Provide Operations Update on November 13th
Published on 10/28/2026 at 12:30, 9 hours ago Sterling Expands Mineralized Footprint to 2km With Near Surface Intercept in 850m Eastern Step Out
Published on 10/28/2026 at 12:30, 9 hours ago Ameriwest Reports Additional High-Grade Copper Results from Historical Drill Core at Bornite Including 71.0 Feet (21.6 Meters) at 8.08% CuEq
Published on 10/28/2026 at 12:15, 9 hours 15 minutes ago BULGOLD Expands Strategic Exploration Position Around the Lutila Gold Project with Two New Exploration Licences
Published on 10/28/2026 at 21:15, 14 minutes ago Amrize Completes $1 Billion Share Repurchase Program
Published on 10/28/2026 at 20:36, 53 minutes ago Vonovia’s Core Business Remains Resilient as Higher Financing Costs and Weaker Transaction Business Shape 2027 Guidance and 2028 Objectives
Published on 10/28/2026 at 20:35, 54 minutes ago EQS-Adhoc: Vonovia specifies Guidance for 2026 and adjusts Guidance for Organic Rent Growth and Operating Free Cash Flow for 2026; Publication of initial 2027 Guidance and revision of 2028 Objectives
Published on 10/28/2026 at 20:18, 1 hour 11 minutes ago Turkiye Garanti Bankasi A.S.: BRSA Consolidated Earnings Presentation dated 30 September 2026
Published on 10/28/2026 at 17:45, 3 hours 45 minutes ago VOGO obtains FIBA (International Basketball Federation) Approval for its Instant Replay System.
Published on 10/28/2026 at 17:45, 3 hours 45 minutes ago Successful issue of a € 6.0 billion bond as part of the financing of the PTC acquisition
Published on 10/28/2026 at 17:45, 3 hours 45 minutes ago Groupe CRIT : Revenue over 9 months 2026 : €2.55 billion (+2.2% organic growth).
Published on 10/28/2026 at 17:45, 3 hours 45 minutes ago Infotel : Acceleration of growth in Q3 2026: €77.9m (+11.3%). Confirmation of growth and profitability targets for 2026 as a whole.
